StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)

Close on Nov 17, 2026Market cap $10.23MP/E –Yield –

TScan Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

TScan Therapeutics's total debt was $32.78M at Jun 30, 2026. For fiscal 2025 it was $32.53M, up 1.4% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$32.53M+1.4%
FY2024Dec 31, 2024$32.07M+6.7%
FY2023Dec 31, 2023$30.05M+2.6%
FY2022Dec 31, 2022$29.29M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$32.78M+1.5%
Q1 FY2026Mar 31, 2026$32.65M+1.5%
Q4 FY2025Dec 31, 2025$32.53M+1.4%
Q3 FY2025Sep 30, 2025$32.41M+5.8%
Q2 FY2025Jun 30, 2025$32.30M+6.1%
Q1 FY2025Mar 31, 2025$32.18M+6.4%
Q4 FY2024Dec 31, 2024$32.07M+6.7%
Q3 FY2024Sep 30, 2024$30.65M+2.3%
Q2 FY2024Jun 30, 2024$30.45M+2.4%
Q1 FY2024Mar 31, 2024$30.25M+2.5%
Q4 FY2023Dec 31, 2023$30.05M+2.6%
Q3 FY2023Sep 30, 2023$29.95M+3.0%
Q2 FY2023Jun 30, 2023$29.72M–
Q1 FY2023Mar 31, 2023$29.50M–
Q4 FY2022Dec 31, 2022$29.29M–
Q3 FY2022Sep 30, 2022$29.07M–

More TScan Therapeutics figures

See a number that looks wrong?